New Topical Treatments Offer Hope for Hyperhidrosis Sufferers in South Korea

For the estimated 28,000 individuals in South Korea suffering from hyperhidrosis—the condition of excessive sweating beyond what is necessary for thermoregulation—relief has often been elusive. Historically, managing this often-debilitating condition meant resorting to invasive procedures like sympathectomy (surgical nerve cutting) or recurring Botox injections, options that carry their own risks and costs. Oral medications, while available, often come with a burden of systemic side effects. This limited therapeutic landscape has meant many have simply endured the daily discomfort and social anxiety associated with excessive sweating.

“

Hyperhidrosis is a skin condition where sweating occurs in amounts exceeding what is necessary for body temperature regulation.

However, a significant shift is underway in the treatment of hyperhidrosis in South Korea, driven by the introduction of novel topical therapies. While over-the-counter aluminum chloride preparations have been available, they function by physically blocking sweat ducts, which can lead to skin irritation and potential long-term changes in sweat gland structure. The recent arrival of prescription-strength topical treatments marks a more sophisticated approach.

One such advancement is the sopronirium bromide gel, recently approved and available in South Korea. Unlike older methods, this new agent targets the root of the problem by inhibiting the neurotransmitter acetylcholine, which signals sweat glands to activate. By binding to muscarinic receptors on the eccrine sweat glands, it effectively dampens the nerve impulses responsible for sweating. Clinical studies suggest rapid improvement within a week for many patients, with sustained efficacy over 52 weeks. Crucially, because it is applied topically and metabolized quickly, it offers a favorable side effect profile compared to systemic anticholinergic drugs, minimizing concerns about widespread adverse reactions.

“

The new sopronirium bromide formulation blocks the action of acetylcholine, thereby inhibiting sweat secretion.

While this new topical treatment represents a significant step forward, particularly for primary axillary hyperhidrosis, it's important to note that treatment decisions should remain individualized. Consultation with a dermatologist is essential to assess the severity of symptoms, potential side effects, and determine the most appropriate course of action. The availability of more targeted and effective topical treatments offers renewed hope for those seeking to manage hyperhidrosis and regain control over their daily lives.

“

Treatment duration and methods should be determined by a dermatologist based on the patient's symptom severity and response.